The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
16 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $8,506,978 in first-year total cost, median $490,053.
Most frequent study sections
- Special Emphasis Panel[ZRG1 VH-F (55)]8
- Special Emphasis Panel[ZRG1 VH-D (55)]4
- Special Emphasis Panel[ZRG1 VH-A (51)]1
- Special Emphasis Panel[ZRG1 VH-F (50)]1
- Special Emphasis Panel[ZRG1-VH-F(50)S]1
Most frequent institutions
- VITALANT3
- COLUMBIA UNIVERSITY HEALTH SCIENCES2
- EMORY UNIVERSITY2
- NEW YORK BLOOD CENTER2
- BLOODWORKS1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Pan-Genomic Approaches for Comprehensive Blood Screening of Novel or Emerging Infectious Agents2R01HL105704-06 | CHIU, CHARLES YEN | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $733,979 | ZRG1 |
| 2017 | Cyokine control of red blood cell alloimmunization1R01HL134691-01 | LUCKEY, CHANCE MARION JOHN | UNIVERSITY OF VIRGINIA, VA | $519,149 | ZRG1 |
| 2016 | Red blood cells from iron-deficient donors: recovery and storage quality1R01HL133049-01 | HOD, ELDAD ARIESPITALNIK, STEVEN L | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $776,564 | ZRG1 |
| 2016 | Effects of blood conservation and donor characteristics on transfused patient outcomes in a large community hospital network1R01HL126130-01A1 | ROUBINIAN, NAREG | VITALANT, AZ | $560,967 | ZRG1 |
| 2016 | Generation of alloantigen-specific Designer Platelets for diagnostic and investigative use1R01HL130054-01 | NEWMAN, PETER J | VERSITI WISCONSIN, INC., WI | $510,464 | ZRG1 |
| 2016 | Mechanisms controlling transfusion-associated antibody responses in SCD alloimmunization1R01HL130139-01 | YAZDANBAKHSH, KARINA | NEW YORK BLOOD CENTER, NY | $426,500 | ZRG1 |
| 2016 | Mechanisms regulating alloimmunization and tolerance with pathogen reduction and transfusion of allogeneic platelets1R01HL133024-01 | JACKMAN, RACHAEL PERETZ | VITALANT, AZ | $356,175 | ZRG1 |
| 2016 | VO2 Max: In Vivo Model for Functional Red Cell Testing. Can RECESS be explained?1R56HL130186-01 | BENNETT-GUERRERO, ELLIOTT | STATE UNIVERSITY NEW YORK STONY BROOK, NY | $347,496 | ZRG1 |
| 2015 | GPIbalpha shedding and platelet clearance1R01HL123984-01A1 | LI, RENHAO | EMORY UNIVERSITY, GA | $395,848 | ZRG1 |
| 2015 | Red Cell Transfusion-associated Necrotizing Enterocolitis in Premature Infants1R01HL124078-01A1 | MAHESHWARI, AKHIL | UNIVERSITY OF SOUTH FLORIDA, FL | $384,890 | ZRG1 |
| 2014 | Adverse effects of RBC transfusions: A unifying hypothesis2R01HL095479-05A1 | ROBACK, JOHN D | EMORY UNIVERSITY, GA | $871,475 | ZRG1 |
| 2014 | Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications1R01HL121232-01 | KOR, DARYL JWELSBY, IAN J | MAYO CLINIC ROCHESTER, MN | $655,451 | ZRG1 |
| 2014 | T cell Immunoregulation of alloimmunization in sickle cell disease1R01HL121415-01A1 | YAZDANBAKHSH, KARINA | NEW YORK BLOOD CENTER, NY | $630,879 | ZRG1 |
| 2014 | Persistence of WNV RNA in blood and the risk of transfusion-transmission1R56HL120970-01 | LANTERI, MARION | VITALANT, AZ | $469,641 | ZRG1 |
| 2014 | Prevention of Platelet Alloimmunization by Costimulatory Blockade1R01HL114525-01A1 | ZIMRING, JAMES C. | BLOODWORKS, WA | $467,500 | ZRG1 |
| 2014 | The safety of red blood cell transfusions1R01HL121275-01A1 | HOD, ELDAD ARIE | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $400,000 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.